This first-to-market technology gives patient service teams nearly immediate insight into patient coverage from both pharmacy and major medical plans, the potential need for prior authorization support, and any financial responsibilities impacting patient access and speed to treatment.

Yesterday Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration, the first Alzheimer’s treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The agency’s decision marks a new milestone for a fatal disease that has eluded drugmakers’ efforts for decades.

A federal judge in Texas on Thursday blocked Obamacare’s mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP), at no cost to patients.

The U.S. government on May 11 will end the COVID-19 Public Health Emergency (PHE) that allowed millions of Americans to receive vaccines, tests, and treatments at no cost during the pandemic.

An ECRI report identifies reasons medications have been under-utilized and urges action to help combat America’s obesity epidemic.